# Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

> **NCT04623931** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Anaplastic Astrocytoma, IDH-Wildtype
- Anaplastic Oligoastrocytoma
- Anaplastic Oligodendroglioma
- Diffuse Astrocytoma, IDH-Wildtype
- Glioblastoma
- Oligoastrocytoma
- Oligodendroglioma
- WHO Grade II Glioma
- WHO Grade III Glioma

## Interventions

- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04623931
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04623931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04623931, "Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04623931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*